{
    "ticker": "GLPG",
    "name": "Galapagos NV",
    "description": "Galapagos NV is a biotechnology company focused on the discovery and development of innovative medicines with a primary focus on inflammatory diseases and fibrosis. Founded in 1999 and headquartered in Mechelen, Belgium, Galapagos has built a robust pipeline of drug candidates powered by its proprietary target discovery platform and extensive drug development capabilities. The company is known for its commitment to research and development, leveraging insights from genetics and disease biology to identify and validate novel therapeutic targets. Galapagos has partnered with major pharmaceutical companies, including Gilead Sciences, to advance its clinical programs. A key area of focus is the development of therapies for conditions like rheumatoid arthritis and cystic fibrosis, where unmet medical needs remain significant. Galapagos aims to bring transformative therapies to patients and improve their quality of life, underpinned by a strong commitment to scientific excellence and patient-centric approaches. The company\u2019s innovative mindset and collaborative spirit drive its mission to explore new frontiers in biotechnology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Mechelen, Belgium",
    "founded": "1999",
    "website": "https://www.glpg.com",
    "ceo": "Onno van de Stolpe",
    "social_media": {
        "twitter": "https://twitter.com/GalapagosNV",
        "linkedin": "https://www.linkedin.com/company/galapagos-nv/"
    },
    "investor_relations": "https://www.glpg.com/investor-relations",
    "key_executives": [
        {
            "name": "Onno van de Stolpe",
            "position": "CEO"
        },
        {
            "name": "Wim De Geest",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Drug Candidates",
            "products": [
                "Filgotinib",
                "GLPG-1972",
                "GLPG-1205"
            ]
        }
    ],
    "seo": {
        "meta_title": "Galapagos NV | Innovative Biotechnology and Medicines",
        "meta_description": "Explore Galapagos NV, a leading biotechnology company dedicated to developing innovative medicines for inflammatory diseases and fibrosis. Learn about their pipeline and commitment to research.",
        "keywords": [
            "Galapagos",
            "Biotechnology",
            "Pharmaceuticals",
            "Filgotinib",
            "Inflammatory Diseases",
            "Fibrosis"
        ]
    },
    "faq": [
        {
            "question": "What is Galapagos known for?",
            "answer": "Galapagos is known for its innovative drug development in the fields of inflammatory diseases and fibrosis."
        },
        {
            "question": "Who is the CEO of Galapagos?",
            "answer": "Onno van de Stolpe is the CEO of Galapagos NV."
        },
        {
            "question": "Where is Galapagos headquartered?",
            "answer": "Galapagos is headquartered in Mechelen, Belgium."
        },
        {
            "question": "What are Galapagos's main products?",
            "answer": "Galapagos's main products include drug candidates like Filgotinib, GLPG-1972, and GLPG-1205."
        },
        {
            "question": "When was Galapagos founded?",
            "answer": "Galapagos was founded in 1999."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "VRTX"
    ],
    "related_stocks": [
        "GILD",
        "ABBV",
        "JNJ",
        "MRNA"
    ]
}